Modelling the impact of antiretroviral use in resource-poor settings

被引:124
作者
Baggaley, Rebecca F. [1 ]
Garnett, Geoff P. [1 ]
Ferguson, Neil M. [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis & Epidemiol, London, England
关键词
D O I
10.1371/journal.pmed.0030124
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The anticipated scale-up of antiretroviral therapy (ART) in high-prevalence, resource-constrained settings requires operational research to guide policy on the design of treatment programmes. Mathematical models can explore the potential impacts of various treatment strategies, including timing of treatment initiation and provision of laboratory monitoring facilities, to complement evidence from pilot programmes. Methods and Findings A deterministic model of HIV transmission incorporating ART and stratifying infection progression into stages was constructed. The impact of ART was evaluated for various scenarios and treatment strategies, with different levels of coverage, patient eligibility, and other parameter values. These strategies included the provision of laboratory facilities that perform CD4 counts and viral load testing, and the timing of the stage of infection at which treatment is initiated. In our analysis, unlimited ART provision initiated at late-stage infection (AIDS) increased prevalence of HIV infection. The effect of additionally treating pre-AIDS patients depended on the behaviour change of treated patients. Different coverage levels for ART do not affect benefits such as life-years gained per person-year of treatment and have minimal effect on infections averted when treating AIDS patients only. Scaling up treatment of pre-AIDS patients resulted in more infections being averted per person-year of treatment, but the absolute number of infections averted remained small. As coverage increased in the models, the emergence and risk of spread of drug resistance increased. Withdrawal of failing treatment (clinical resurgence of symptoms), immunologic (CD4 count decline), or virologic failure (viral rebound) increased the number of infected individuals who could benefit from ART, but effectiveness per person is compromised. Only withdrawal at a very early stage of treatment failure, soon after viral rebound, would have a substantial impact on emergence of drug resistance. Conclusions Our analysis found that ART cannot be seen as a direct transmission prevention measure, regardless of the degree of coverage. Counselling of patients to promote safe sexual practices is essential and must aim to effect long-term change. The chief aims of an ART programme, such as maximised number of patients treated or optimised treatment per patient, will determine which treatment strategy is most effective.
引用
收藏
页码:493 / 504
页数:12
相关论文
共 40 条
  • [21] Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure
    Miller, V
    Sabin, C
    Hertogs, K
    Bloor, S
    Martinez-Picado, J
    D'Aquila, R
    Larder, B
    Lutz, T
    Gute, P
    Weidmann, E
    Rabenau, H
    Phillips, A
    Staszewski, S
    [J]. AIDS, 2000, 14 (18) : 2857 - 2867
  • [22] Theme 7 - Genotypic resistance tests for the management of patients with viro-immunological discordant response to highly active antiretroviral therapy
    Moroni, M
    Rusconi, S
    [J]. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2003, 35 : 85 - 87
  • [23] Tackling HIV in resource poor countries
    Mukherjee, JS
    Farmer, PE
    Niyizonkiza, D
    McCorkle, L
    Vanderwarker, C
    Teixeira, P
    Kim, JY
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2003, 327 (7423): : 1104 - 1106
  • [24] Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy
    Nicastri, E
    Sarmati, L
    d'Ettorre, G
    Palmisano, L
    Parisi, SG
    Uccella, I
    Rianda, A
    Concia, E
    Vullo, V
    Vella, S
    Andreoni, M
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2003, 69 (01) : 1 - 6
  • [25] Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata
    Palella, FJ
    Deloria-Knoll, M
    Chmiel, JS
    Moorman, AC
    Wood, KC
    Greenberg, AE
    Holmberg, SD
    [J]. ANNALS OF INTERNAL MEDICINE, 2003, 138 (08) : 620 - 626
  • [26] Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
    Palella, FJ
    Delaney, KM
    Moorman, AC
    Loveless, MO
    Fuhrer, J
    Satten, GA
    Aschman, DJ
    Holmberg, SD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (13) : 853 - 860
  • [27] HIV/AIDS in Africa: treatment as a right and strategies for fair implementation. False assumptions on the basis of a minimalistic approach
    Palombi, L
    Perno, CF
    Marazzi, MC
    [J]. AIDS, 2005, 19 (05) : 536 - 537
  • [28] Viral load and heterosexual transmission of human immunodeficiency virus type 1
    Quinn, TC
    Wawer, MJ
    Sewankambo, N
    Serwadda, D
    Li, CJ
    Wabwire-Mangen, F
    Meehan, MO
    Lutalo, T
    Gray, RH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (13) : 921 - 929
  • [29] Integrating HIV prevention and treatment:: From slogans to impact
    Salomon, JA
    Hogan, DR
    Stover, J
    Stanecki, KA
    Walker, N
    Ghys, PD
    Schwartländer, B
    [J]. PLOS MEDICINE, 2005, 2 (01) : 50 - 56
  • [30] Characterization of nef gene of HIV type 1 in highly active antiretroviral therapy treated AIDS patients with discordance between viral load and CD4+ T cell counts
    Saurya, S
    Lichtenstein, Z
    Karpas, A
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2002, 18 (13) : 983 - 987